ILMN Illumina, Inc.

Price (delayed)

$323.55

Market cap

$47.24B

P/E Ratio

68.69

Dividend/share

N/A

EPS

$4.71

Enterprise value

$47.31B

Sector: Healthcare
Industry: Diagnostics & Research
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Highlights

The equity has increased by 5% YoY
The gross margin has grown by 2% YoY
The quick ratio has contracted by 45% YoY and by 9% from the previous quarter
The stock's price to earnings (P/E) is 31% more than its 5-year quarterly average of 52.5 and 29% more than its last 4 quarters average of 53.2

Key stats

What are the main financial stats of ILMN
Market
Shares outstanding
146M
Market cap
$47.24B
Enterprise value
$47.31B
Valuations
Price to earnings (P/E)
68.69
Price to book (P/B)
10.42
Price to sales (P/S)
14.19
EV/EBIT
51.09
EV/EBITDA
42.7
EV/Sales
14.12
Earnings
Revenue
$3.35B
EBIT
$926M
EBITDA
$1.11B
Free cash flow
$1.05B
Per share
EPS
$4.71
Free cash flow per share
$7.12
Book value per share
$31.04
Revenue per share
$22.8
TBVPS
$42.16
Balance sheet
Total assets
$7.25B
Total liabilities
$2.69B
Debt
$1.84B
Equity
$4.56B
Working capital
$3.08B
Liquidity
Debt to equity
0.4
Current ratio
3.76
Quick ratio
3.28
Net debt/EBITDA
0.07
Margins
EBITDA margin
33.1%
Gross margin
70.3%
Net margin
20.7%
Operating margin
25.7%
Efficiency
Return on assets
9.6%
Return on equity
15.2%
Return on invested capital
17.4%
Return on capital employed
15.1%
Return on sales
27.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ILMN stock price

How has the Illumina stock price performed over time

Financial performance

How have Illumina's revenue and profit performed over time
Revenue
$3.35B
Gross profit
$2.36B
Operating income
$861M
Net income
$693M
Gross margin
70.3%
Net margin
20.7%
ILMN's net income is down by 26% since the previous quarter and by 26% year-on-year
Illumina's net margin has decreased by 25% YoY and by 22% QoQ
The operating income has decreased by 11% from the previous quarter
Illumina's operating margin has decreased by 6% from the previous quarter but it has increased by 3.2% YoY

Growth

What is Illumina's growth rate over time

Valuation

What is Illumina stock price valuation
P/E
68.69
P/B
10.42
P/S
14.19
EV/EBIT
51.09
EV/EBITDA
42.7
EV/Sales
14.12
The stock's price to earnings (P/E) is 31% more than its 5-year quarterly average of 52.5 and 29% more than its last 4 quarters average of 53.2
Illumina's EPS has decreased by 26% QoQ and by 26% YoY
The price to book (P/B) is 8% lower than the 5-year quarterly average of 11.3 but 2.2% higher than the last 4 quarters average of 10.2
The equity has increased by 5% YoY
ILMN's P/S is 16% above its 5-year quarterly average of 12.2 and 6% above its last 4 quarters average of 13.4
Illumina's revenue has decreased by 6% QoQ

Efficiency

How efficient is Illumina business performance
The ROE has contracted by 37% YoY and by 27% from the previous quarter
The company's return on assets fell by 28% YoY and by 27% QoQ
ILMN's return on invested capital is down by 22% year-on-year and by 17% since the previous quarter
Illumina's return on sales has decreased by 16% YoY and by 12% QoQ

Dividends

What is ILMN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ILMN.

Financial health

How did Illumina financials performed over time
The total assets is 170% more than the total liabilities
The quick ratio has contracted by 45% YoY and by 9% from the previous quarter
The current ratio has contracted by 45% YoY and by 8% from the previous quarter
Illumina's debt is 60% lower than its equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.